The article offers information on a study on CD19-directed chimeric antigen receptor (CAR)-expressing T cells that have shown dramatic results in the treatment of acute lymphoblastic leukemia and B-cell lymphoma activity. It informs that The CD19 antigen is restricted to the B-cell lineage in general and is not limited to the malignant clone.